→ Protagonist Therapeutics {PTGX}, a tiny public company in Newark, CA, has inked a securities purchase deal totaling $22 million in shares to sort out plans for its former lead program in inflammatory bowel diseases. The new funds will go towards PTG-100, an oral alpha-4-beta-7 integrin antagonist peptide, which was previously in a Phase IIb trial for ulcerative colitis before it was discontinued. Now, the company says its under evaluation for other IBD indications. The biotech is selling 2.75 million shares to investors including BVF Partners and their affiliate. The investors also got five-year warrants to buy up 1.375 million shares at $15 per share.

→ FDA staffers say Paratek’s $PRTK new antibiotic, called omadacycline, has proven not inferior to current treatments for bacterial skin infections and pneumonia. That news comes a couple days before an advisory committee will evaluate the drug’s safety and efficacy. Read the briefing here.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 31,500+ biopharma executives who read Endpoints News every day.